Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Pediatric Gastroenterology and Nutrition"
DOI: 10.1097/mpg.0000000000003757
Abstract: In January of 2023, the first adalimumab biosimilar became available in the United States for treatment of inflammatory bowel disease (IBD). Seven more adalimumab biosimilars are set to become available over the summer and fall… read more here.
Keywords: biosimilars considerations; considerations pediatric; wave adalimumab; riding wave ... See more keywords